Indirect Costs of Inflammatory Bowel Diseases: A Comparison of Patient-Reported Outcomes Across 12 European Countries

Overview

Journal Inflamm Bowel Dis

Publisher Oxford University Press

Specialty Gastroenterology

Date 2022 Jul 6

PMID 35792501

Authors

Przemyslaw Holko

Pawel Kawalec

Magdalena Sajak-Szczerba

Luisa Avedano

Malgorzata Mossakowska

Affiliations

Soon will be listed here.

Abstract

Background: National studies report a high variability of indirect costs of inflammatory bowel disease (IBD). In this study, selected aspects of the societal burden of IBDs were compared between 12 European countries.

Methods: A questionnaire-based study among adult patients with IBD was performed. Data on patient characteristics, productivity loss, and informal care were collected. The costs of productivity loss were assessed from the social perspective. The cost of absenteeism and presenteeism was valuated using the gross domestic product per worker. Informal care was measured by time inputs of relatives and friends to assist patients. Productivity loss among informal caregivers outside their paid work was valuated with the average wage. The results were adjusted for confounders and multiplicity.

Results: Responses from 3687 patients (67% employed) were analyzed. Regular activity (outside paid work) impairment did not differ between countries, but a significant difference in informal care and productivity loss was observed. There were no differences in indirect costs between the types of IBD across the countries. The mean annual cost of absenteeism, presenteeism, and informal care varied from €1253 (Bulgaria) to €7915 (Spain), from €2149 (Bulgaria) to €14 524 (Belgium), and from €1729 (Poland) to €12 063 (Italy), respectively. Compared with patients with active disease, those with IBD in remission showed a lower indirect cost by 54% (presenteeism, P < .001) or 75% (absenteeism, informal care, P < .001).

Conclusions: The study showed a high relevance of the indirect cost of IBD in the context of economic evaluation, as well as a between-country variability of work-related impairment or informal care.

Citing Articles

Dissecting the rising tide of inflammatory bowel disease among youth in a changing world: insights from GBD 2021.

Chen L, Xu Y, Ai F, Shen S, Luo Y, Li X Int J Colorectal Dis. 2025; 40(1):44.

PMID: 39964411 PMC: 11836149. DOI: 10.1007/s00384-025-04821-0.

Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.

Youssef M, Hossein-Javaheri N, Hoxha T, Mallouk C, Tandon P J Crohns Colitis. 2024; 18(9):1486-1504.

PMID: 38647194 PMC: 11369077. DOI: 10.1093/ecco-jcc/jjae057.

Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries.

Holko P, Kawalec P, Sajak-Szczerba M, Avedano L, Mossakowska M Eur J Health Econ. 2022; 24(7):1073-1083.

PMID: 36261612 PMC: 10406674. DOI: 10.1007/s10198-022-01536-9.

Implications of the changing epidemiology of inflammatory bowel disease in a changing world.

Agrawal M, Jess T United European Gastroenterol J. 2022; 10(10):1113-1120.

PMID: 36251359 PMC: 9752308. DOI: 10.1002/ueg2.12317.

References

Holko P, Kawalec P, Mossakowska M, Pilc A . Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland. PLoS One. 2016; 11(12):e0168586. PMC: 5161376. DOI: 10.1371/journal.pone.0168586. View

Koopmanschap M, van Exel J, van den Berg B, Brouwer W . An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics. 2008; 26(4):269-80. DOI: 10.2165/00019053-200826040-00001. View

van Linschoten R, Visser E, Niehot C, van der Woude C, Hazelzet J, van Noord D . Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther. 2021; 54(3):234-248. PMC: 8361769. DOI: 10.1111/apt.16445. View

Bennebroek Evertsz F, Hoeks C, Nieuwkerk P, Stokkers P, Ponsioen C, Bockting C . Development of the patient Harvey Bradshaw index and a comparison with a clinician-based Harvey Bradshaw index assessment of Crohn's disease activity. J Clin Gastroenterol. 2013; 47(10):850-6. DOI: 10.1097/MCG.0b013e31828b2196. View

Jacobs P, Bissonnette R, Guenther L . Socioeconomic burden of immune-mediated inflammatory diseases--focusing on work productivity and disability. J Rheumatol Suppl. 2011; 88:55-61. DOI: 10.3899/jrheum.110901. View

Krol M, Papenburg J, van Exel J . Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies. Pharmacoeconomics. 2014; 33(2):123-35. DOI: 10.1007/s40273-014-0218-y. View

Lonnfors S, Vermeire S, Greco M, Hommes D, Bell C, Avedano L . IBD and health-related quality of life -- discovering the true impact. J Crohns Colitis. 2014; 8(10):1281-6. DOI: 10.1016/j.crohns.2014.03.005. View

Reilly M, Zbrozek A, Dukes E . The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993; 4(5):353-65. DOI: 10.2165/00019053-199304050-00006. View

van der Valk M, Mangen M, Leenders M, Dijkstra G, van Bodegraven A, Fidder H . Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2012; 63(1):72-9. DOI: 10.1136/gutjnl-2012-303376. View

10.

van den Berg B, Brouwer W, Koopmanschap M . Economic valuation of informal care. An overview of methods and applications. Eur J Health Econ. 2004; 5(1):36-45. DOI: 10.1007/s10198-003-0189-y. View

11.

Bennebroek Evertsz F, Nieuwkerk P, Stokkers P, Ponsioen C, Bockting C, Sanderman R . The patient simple clinical colitis activity index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: a comparison of the P-SCCAI with clinician-based SCCAI and biological markers. J Crohns Colitis. 2012; 7(11):890-900. DOI: 10.1016/j.crohns.2012.11.007. View

12.

Krol M, Brouwer W . How to estimate productivity costs in economic evaluations. Pharmacoeconomics. 2014; 32(4):335-44. DOI: 10.1007/s40273-014-0132-3. View

13.

Armuzzi A, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D . The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. BMC Gastroenterol. 2020; 20(1):18. PMC: 6975026. DOI: 10.1186/s12876-020-1164-0. View

14.

Gregori D, Petrinco M, Bo S, Desideri A, Merletti F, Pagano E . Regression models for analyzing costs and their determinants in health care: an introductory review. Int J Qual Health Care. 2011; 23(3):331-41. DOI: 10.1093/intqhc/mzr010. View

15.

Zhang W, Bansback N, Anis A . Measuring and valuing productivity loss due to poor health: A critical review. Soc Sci Med. 2010; 72(2):185-92. DOI: 10.1016/j.socscimed.2010.10.026. View

16.

Odes S, Vardi H, Friger M, Wolters F, Russel M, Riis L . Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006; 131(3):719-28. DOI: 10.1053/j.gastro.2006.05.052. View

17.

Shafer L, Shaffer S, Witt J, Nugent Z, Bernstein C . IBD Disability Index Is Associated With Both Direct and Indirect Costs of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021; 28(8):1189-1197. DOI: 10.1093/ibd/izab248. View

18.

Ruiz-Casas L, Evans J, Rose A, Pedra G, Lobo A, Finnegan A . The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe. BMC Gastroenterol. 2021; 21(1):456. PMC: 8645093. DOI: 10.1186/s12876-021-02028-5. View

19.

van Gennep S, Evers S, Rietdijk S, Gielen M, de Boer N, Gecse K . High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study. Inflamm Bowel Dis. 2020; 27(3):352-363. PMC: 7885332. DOI: 10.1093/ibd/izaa082. View

20.

Mandel M, Michael M, Balint A, Lovasz B, Gulacsi L, Strbak B . Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ. 2014; 15 Suppl 1:S121-8. DOI: 10.1007/s10198-014-0603-7. View